Mathematical models of cancer dormancy

The objective of this paper is to present preliminary mathematical models of the interaction between tumor and antibody for the murine BCL1 lymphoma and illustrate how this interaction leads to dormancy of the tumor. We explicitly model the induction by the immune response of cell cycle arrest and apoptosis of the tumor cells. In the absence of large amounts of quantitative data and because the models are preliminary, they are deliberately simple. We neglect, for example, spatial effects on this lymphoid tumor and the synergistic effect of antigen-specific T cells. A comparison of alternative models shows that, although vaccination is necessary to stimulate a sufficient immune response to control tumor growth, boosting of the antibody response by the tumor itself is vital to the mechanisms that maintain dormancy. We determine parameters that control the size of the dormant tumors, and the fraction of proliferating cells. Finally, we discuss the implications for tumor immunotherapy.

[1]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[2]  J. Uhr,et al.  Monoclonal antibodies as agonists: an expanded role for their use in cancer therapy. , 1994, Cancer research.

[3]  Nicola Bellomo,et al.  A Survey of Models for Tumor-Immune System Dynamics , 1996 .

[4]  R. Woodland,et al.  Naive B Lymphocytes Undergo Homeostatic Proliferation in Response to B Cell Deficit1 , 2002, The Journal of Immunology.

[5]  G. D. Knott,et al.  Modeling tumor regrowth and immunotherapy , 2001 .

[6]  Tumor Dormancy and Cell Signaling. II. Antibody as an Agonist in Inducing Doi~iiiancy of a B Cell Lymphoma in SCID Mice By E. Racila,* R. H. Scheuermann,~ L. J. Picker,~ E. Yefenof,$ , 1995 .

[7]  A. George,et al.  Idiotypic vaccination as a treatment for a B cell lymphoma. , 1988, Journal of immunology.

[8]  L. Preziosi,et al.  Modelling and mathematical problems related to tumor evolution and its interaction with the immune system , 2000 .

[9]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[10]  A. McLean,et al.  Resource competition as a mechanism for B cell homeostasis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Uhr,et al.  Cancer dormancy: studies of the murine BCL1 lymphoma. , 1991, Cancer research.

[12]  S. Eccles,et al.  Immunologically-mediated restraint of latent tumour metastases , 1975, Nature.

[13]  R. Scheuermann,et al.  Tumour dormancy and cell signalling--III: Role of hypercrosslinking of IgM and CD40 on the induction of cell cycle arrest and apoptosis in B lymphoma cells. , 1995, Therapeutic immunology.

[14]  R. Scheuermann,et al.  Cancer dormancy: Opportunities for new therapeutic approaches , 1997, Nature Medicine.

[15]  M. Nowak,et al.  Oncogenes, anti-oncogenes and the immune response to cancer : a mathematical model , 1992, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[16]  Stuart H. Orkin,et al.  Diversification of haematopoietic stem cells to specific lineages , 2000, Nature Reviews Genetics.

[17]  P. Isakson,et al.  BCL1, a Murine Model for Chronic Lymphocytic Leukemia: Use of the Surface Immunoglobulin Idiotype for the Detection and Treatment of Tumor , 1979, Immunological reviews.

[18]  J. Uhr,et al.  Tumor dormancy. I. Regression of BCL1 tumor and induction of a dormant tumor state in mice chimeric at the major histocompatibility complex. , 1986, Journal of immunology.

[19]  P. Hahnfeldt,et al.  Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.

[20]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[21]  L. Picker,et al.  Lymphocyte Homing and Homeostasis , 1996, Science.

[22]  J A Sherratt,et al.  Modelling the macrophage invasion of tumours: effects on growth and composition. , 1998, IMA journal of mathematics applied in medicine and biology.

[23]  A Romano,et al.  Analysis of a "phase transition" from tumor growth to latency. , 2000, Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics.

[24]  R. Scheuermann,et al.  Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice , 1995, The Journal of experimental medicine.

[25]  B. Fisher,et al.  Experimental Evidence in Support of the Dormant Tumor Cell , 1959, Science.

[26]  R. Miller,et al.  Therapy of lymphoma directed at idiotypes. , 1990, Journal of the National Cancer Institute. Monographs.

[27]  J. Folkman,et al.  Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.

[28]  B. Rocha,et al.  Population biology of lymphocytes: the flight for survival. , 2000, Annual review of immunology.

[29]  Y. W. Huang,et al.  Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established. , 1997, Blood.

[30]  F. Stevenson,et al.  Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surfaces. , 1980, British Journal of Cancer.

[31]  D. P. Cooney,et al.  Spontaneous regression of non‐Hodgkin's lymphoma: A report of nine cases , 1980, Cancer.

[32]  G. Riethmüller,et al.  Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma , 1994, The Lancet.

[33]  R. Scheuermann,et al.  Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. , 1999, Journal of immunology.

[34]  D. Wilbur,et al.  Malignant Melanoma with Delayed Metastatic Growths , 1931 .

[35]  S. Strober,et al.  Spontaneous murine B-cell leukaemia , 1978, Nature.

[36]  G. Hadfield The Dormant Cancer Cell* , 1954, British medical journal.

[37]  A. Perelson,et al.  Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.

[38]  J. Marx Monoclonal antibodies in cancer. , 1982, Science.

[39]  A. Ullrich,et al.  Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic , 1991, Journal of Clinical Immunology.

[40]  H M Byrne,et al.  The effect of time delays on the dynamics of avascular tumor growth. , 1997, Mathematical biosciences.

[41]  R. Kerbel Monoclonal Antibodies in Cancer Therapy: An Overview , 1999, Cancer and Metastasis Reviews.

[42]  Thomas Boehm,et al.  Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.

[43]  A. George,et al.  Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. , 1987, Journal of immunology.

[44]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[45]  H. Modjtahedi,et al.  Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. , 1994, Cancer research.

[46]  Y. Moshel,et al.  Tumor‐cell vaccination induces tumor dormancy in a murine model of B‐cell leukemia/lymphoma (BCL1) , 1996, International journal of cancer.